The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 2, 2012, Pages 77-87

  Samuel, Nardin ^a   Hudson, Thomas J ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; INIPARIB; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; TRANSCRIPTOME; TRASTUZUMAB; VEMURAFENIB;

ADVANCED CANCER; BRAF GENE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CDH10 GENE; DPP6 GENE; DRUG EFFECT; DRUG EFFICACY; EXOME; GATA6 GENE; GENE DOSAGE; GENE EXPRESSION REGULATION; GENE TECHNOLOGY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HIGH THROUGHPUT SEQUENCING; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MELANOMA; METASTASIS; MLL3 GENE; MUC1 GENE; ONCOGENE K RAS; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SMAD4 GENE; SMURF1 GENE; SOMATIC MUTATION; STRUCTURAL GENOMICS; TRANSCRIPTOMICS; TUMOR SUPPRESSOR GENE;

CARCINOMA, PANCREATIC DUCTAL; DNA, NEOPLASM; HUMANS; MUTATION; PANCREAS; PANCREATIC NEOPLASMS;

EID: 84856955522     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2011.215     Document Type: Review

References (110)

1. Yeo, T. P. et al. Pancreatic cancer. Curr. Probl. Cancer 26, 176-275 (2002).
2. Jemal, A., Seigel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
3. Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N. & DePinho, R. A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20, 1218-1249 (2006). (Pubitemid 43727584)
4. Feldmann, G. & Maitra, A. Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J. Mol. Diagn. 10, 111-122 (2008). (Pubitemid 351428392)
5. Gräntzdörffer, I., Carl-McGrath, S., Ebert, M. P. & Röcken, C. Proteomics of pancreatic cancer. Pancreas 36, 329-336 (2008). (Pubitemid 351591573)
6. Li, D., Xie, K., Wolff, R. & Abbruzzese, J. L. Pancreatic cancer. Lancet 363, 1049-1057 (2004). (Pubitemid 38410779)
7. Klöppel, G., Solcia, E., Longnecker, D. S., Capella, C. & Sobin, L. H. in International Histological Classification of Tumours 2nd edn 1-61 (Springer/World Health Organization, Berlin, 1998).
8. Hruban, R. H., Goggins, M., Parsons, J. & Kern, S. E. Progression model for pancreatic cancer. Clin. Cancer Res. 6, 2969-2972 (2000). (Pubitemid 30637716)
9. Buchholz, M. et al. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 24, 6626-6636 (2005). (Pubitemid 41486793)
10. Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
11. Chu, G. C., Kimmelman, A. C., Hezel, A. F. & DePinho, R. A. Stromal biology of pancreatic cancer. J. Cell. Biochem. 101, 887-907 (2007). (Pubitemid 47040870)
12. Neesse, A. et al. Stromal biology and therapy in pancreatic cancer. Gut 60, 861-868 (2011).
13. Wang, Z. et al. Pancreatic cancer: understanding and overcoming chemoresistance. Nat. Rev. Gastroenterol. Hepatol. 8, 27-33 (2011).
14. Wang, Z. et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 69, 2400-2407 (2009).
15. Shah, A. N. et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. 14, 3629-3637 (2007). (Pubitemid 350160137)
16. Hermann, P. C. et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323 (2007). (Pubitemid 47355323)
17. Hong, S. P., Wen, J., Bang, S., Park, S. & Song, S. Y. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int. J. Cancer 125, 2323-2331 (2009).
18. Campbell, P. J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113 (2010).
19. Biankin, A. V. & Hudson, T. J. Somatic variation and cancer: therapies lost in the mix. Hum. Genet. 130, 79-91 (2011).
20. Hong, S. M., Park, J. Y., Hruban, R. H. & Goggins, M. Molecular signatures of pancreatic cancer. Arch. Pathol. Lab. Med. 135, 716-727 (2011).
21. Harris, T. J. & McCormick, F. The molecular pathology of cancer. Nat. Rev. Clin. Oncol. 7, 251-265 (2010).
22. Lynch, H. T. et al. Familial pancreatic cancer: a review. Semin. Oncol. 23, 251-275 (1996). (Pubitemid 26120245)
23. Bignell, G. R. et al. Signatures of mutation and selection in the cancer genome. Nature 463, 893-898 (2010).
24. Bardeesy, N. & DePinho, R. A. Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2, 897-909 (2002). (Pubitemid 37328891)
25. Hansel, D. E., Kern, S. E. & Hruban, R. H. Molecular pathogenesis of pancreatic cancer. Annu. Rev. Genomics Hum. Genet. 4, 237-256 (2003). (Pubitemid 37392925)
26. Baumgart, M., Heinmöller, E., Horstmann, O., Becker, H. & Ghadimi, B. M. The genetic basis of sporadic pancreatic cancer. Cell. Oncol. 27, 3-13 (2005). (Pubitemid 40387188)
27. Wong, H. H. & Lemoine, N. R. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat. Rev. Gastroenterol. Hepatol. 6, 412-422 (2009).
28. Klimstra, D. S. & Longnecker, D. S. K-ras mutations in pancreatic ductal proliferative lesions. Am. J. Pathol. 145, 1547-1550 (1994). (Pubitemid 24378508)
29. Rozenblum, E. et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57, 1731-1734 (1997). (Pubitemid 27199667)
30. Rachagani, S. et al. Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br. J. Cancer 104, 1038-1048 (2011).
31. Pugliese, V. et al. Pancreatic intraductal sampling during ERCP in patients with chronic pancreatitis and pancreatic cancer: cytologic studies and k-ras-2 codon 12 molecular analysis in 47 cases. Gastrointest. Endosc. 54, 595-599 (2001). (Pubitemid 33666031)
32. Van Laethem, J. L. et al. Relative contribution of Ki-ras gene analysis and brush cytology during ERCP for the diagnosis of biliary and pancreatic diseases. Gastrointest. Endosc. 47, 479-485 (1998).
33. Luttges, J. et al. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer 85, 1703-1710 (1999). (Pubitemid 29169670)
34. Hruban, R. H., Wilentz, R. & Kern, S. E. Genetic progression in the pancreatic ducts. Am. J. Pathol. 156, 1821-1825 (2000). (Pubitemid 30641750)
35. Calhoun, E. S. et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am. J. Pathol. 163, 1255-1260 (2003). (Pubitemid 37175075)
36. Cheng, J. Q. et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl Acad. Sci. USA 93, 3636-3641 (1996). (Pubitemid 26127592)
37. Ruggeri, B. A., Huang, L., Wood, M., Cheng, J. Q. & Testa, J. R. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog. 21, 81-86 (1998). (Pubitemid 28122842)
38. Wallrapp, C. et al. Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene. Cancer Res. 57, 3135-3139 (1997). (Pubitemid 27351725)
39. Caldas, C. et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 8, 27-32 (1994). (Pubitemid 24274057)
40. Ruggeri, B. A. et al. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 7, 1503-1511 (1992).
41. Scarpa, A. et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am. J. Pathol. 142, 1534-1543 (1993). (Pubitemid 24058140)
42. Hahn, S. A. et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350-353 (1996).
43. Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nat. Med. 10, 789-799 (2004). (Pubitemid 39070849)
44. Maitra, A. & Hruban, R. H. Pancreatic cancer. Annu. Rev. Pathol. 3, 157-188 (2008). (Pubitemid 351488279)
45. Wu, X. et al. HOXB7 homeodomain protein is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res. 66, 9527-9534 (2006). (Pubitemid 44623651)
46. Chen, H. et al. Hoxb7 inhibits transgenic HER-2/neu-induced mouse mammary tumor onset but promotes progression and lung metastasis. Cancer Res. 68, 3637-3644 (2008).
47. De Souza Setubal Destro, M. F. et al. Overexpression of HOXB7 homebox gene in oral cancer induces ceullar proliferation and is associated with poor prognosis. Int. J. Oncol. 36, 141-149 (2010).
48. Kim, Y. S., Gum, J. R. Jr, Crawley, S. C., Deng G. & Ho, J. J. Mucin gene and antigen expression in biliopancreatic carcinogenesis. Ann. Oncol. 10 (Suppl. 4), 51-55 (1999).
49. Kim, G. E. et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology 123, 1052-1060 (2002).
50. Monges, G. M. et al. Differential MUC1 expression in normal and neoplastic human pancreatic tissue. An immunohistochemical study of 60 samples. Am. J. Clin. Pathol. 112, 635-640 (1999). (Pubitemid 30214753)
51. Besmer, D. M. et al. Pancreatic ductal adenocarcinoma (PDA) mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res. 71, 4434-4442 (2011).
52. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
53. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
54. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
55. Varela, I. et al. Exome sequencing identifies frequent mutations of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539-542 (2011).
56. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
57. Wood, L. D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113 (2007). (Pubitemid 350134889)
58. Morris, J. P. 4th, Wang, S. C. & Hebrok, M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 10, 683-695 (2010).
59. Stuart, D. & Sellers, W. R. Linking somatic genetic alterations to cancer therapeutics. Curr. Opin. Cell Biol. 21, 304-310 (2009).
60. International Cancer Genome Consortium. International network of cancer genome projects. Nature 464, 993-998 (2010).
61. Suzuki, A. et al. Identification of SMURF1 as a possible target for 7q21.3-221 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization. Cancer Sci. 99, 986-994 (2008). (Pubitemid 351997602)
62. Fu, B., Luo, M., Lakkur, S., Lucito, R. & Iacobuzio-Donahue, C. A. Frequent genomic copy number gain and overexpression of GATA-6 in pancreatic carcinoma. Cancer Biol. Ther. 7, 1593-1601 (2008).
63. Heidenblad, M. et al. Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines. Cancer Res. 64, 3052-3059 (2004). (Pubitemid 38581404)
64. Holzmann, K. et al. Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes. Cancer Res. 64, 4428-4433 (2004). (Pubitemid 38856913)
65. Kitoh, H. et al. Comparative genomic hybridization analysis for pancreatic cancer specimens obtained by endoscopic ultrasonography-guided fine-needle aspiration. J. Gastroenterol. 40, 511-517 (2005). (Pubitemid 40823287)
66. Loukopoulous, P. et al. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinome: identification of genetic indicators that predict patient outcome. Cancer Sci. 98, 392-400 (2007).
67. Zhong, Y. et al. GATA6 activates Wnt signaling in pancreatic cancer by negatively regulating the Wnt antagonist Dickkopf-1. PLoS ONE 6, e22129 (2011).
68. Genomic Health. Oncotype DX [online], http://www.oncotypedx.com/ (2010).
69. Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500-503 (2011).
70. Chelala, C. et al. Pancreatic expression database: a generic model for the organization, integration and mining of complex cancer datasets. BMC Genomics 8, 439 (2007).
71. International Cancer Genome Consortium Data Coordination Center. Data Portal [online], http://dcc.icgc.org (2011).
72. Vincent, A. et al. Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin. Cancer Res. 17, 4341-4354 (2011).
73. Bloomston, M. et al. MircoRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297, 1901-1908 (2007). (Pubitemid 46707844)
74. Dillhoff, M., Lieu, J., Frankel, W., Croce, C. & Bloomston, M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J. Gastrointest. Surg. 12, 2171-2176 (2008).
75. Lee, E. J. et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 120, 1046-1054 (2007).
76. Szafranska, A. E. et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26, 4442-4452 (2007). (Pubitemid 47014466)
77. Zhang, Y. et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J. Surg. 33, 698-709 (2009).
78. Kent, O. A. et al. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol. Ther. 8, 2013-2024 (2009).
79. Burris, H. A. 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413 (1997).
80. Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966 (2007). (Pubitemid 46972777)
81. Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817-1825 (2011).
82. Stratton, M. R. Exploring the genomes of cancer cells: progress and promise. Science 33, 1553-1558 (2011).
83. Esteva, F. J., Yu, D., Hung., M. C. & Horobagyi, G. N. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat. Rev. Clin. Oncol. 7, 98-107 (2010).
84. Genentech. FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Form of Skin Cancer [online], http://www.gene.com/gene/news/press-releases/display.do-method= detail&id=13567 (2011).
85. Villarroel, M. C. et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol. Cancer Ther. 10, 3-8 (2011).
86. Xia, B. et al. Control of BRAC2 cellular and clinical functions by a nuclear partner, PALB2. Mol. Cell 22, 719-729 (2006).
87. Jones, S. et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324, 217 (2009).
88. Couch, F. J. et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 16, 342-346 (2007). (Pubitemid 46383356)
89. Iacobuzio-Donahue, C. A. et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J. Clin. Oncol. 27, 1806-1813 (2009).
90. Armstrong, M. D. et al. An effective personalized approach to a rare tumor: prolonged survival in metastatic pancreatic acinar cell carcinoma based on genetic analysis and cell line development. J. Cancer 2, 142-152 (2011).
91. Solinas-Toldo, S. et al. Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. Cancer Res. 56, 3803-3807 (1996). (Pubitemid 26272032)
92. Mahlamäki, E. H. et al. Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q and losses of 18q, 9p and 15q in pancreatic cancer. Genes Chromosomes Cancer 20, 383-391 (1997). (Pubitemid 27520088)
93. Fukushige, S. et al. Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer 19, 161-169 (1997). (Pubitemid 27278803)
94. Curtis, L. J. et al. Amplification of DNA sequences from chromosome 19q31.1 in human pancreatic cell line. Genomics 53, 42-55 (1998). (Pubitemid 28489645)
95. Ghadimi, M. B. et al. Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas. Am. J. Pathol. 154, 525-536 (1999).
96. Schleger, C., Arens, N., Zentraf, H., Bleyl, U. & Verbeke, C. Identification of frequent chromosomal aberrations in ductal adenocarcinoma of the pancreas by comparative genomic hybridization (CGH). J. Pathol. 191, 27-32 (2000). (Pubitemid 30235645)
97. Shiraishi, K. et al. A comparison of DNA copy number changes detected by comparative genomic hybridization in malignancies of the liver, biliary tract and pancreas. Oncology 60, 151-161 (2001). (Pubitemid 32245334)
98. Harada, T. et al. Detection of genetic alterations in pancreatic cancers by comparative genomic hybridization coupled with tissue microdissection and degenerate oligonucleotide primed polymerase chain reaction. Oncology 62, 251-258 (2002). (Pubitemid 34639059)
99. Mahlamäki, E. H. et al. Frequent amplification of 8q24, 11q, 17q and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer 35, 353-358 (2002). (Pubitemid 35246993)
100. Lin, M., Cai, D. & Luo, M. Identification of chromosomal imbalances in pancreatic carcinoma using comparative genomic hybridization. Chin. Med. J. (Engl.) 116, 1156-1160 (2003). (Pubitemid 37069856)
101. Aguirre, A. J. et al. High resolution characterization of the pancreatic adenocarcinoma genome. Proc. Natl Acad. Sci. USA 101, 9067-9072 (2004). (Pubitemid 38781612)
102. Mahlamäki, E. H. et al. High resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer. Neoplasia 6, 432-439 (2004). (Pubitemid 39411079)
103. Bashyam, M. D. et al. Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia 7, 556-562 (2005). (Pubitemid 40967756)
104. Gysin, S., Rickert, P., Kastury, K. & McMahon, M. Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines. Genes Chromosomes Cancer 44, 37-51 (2005). (Pubitemid 41060195)
105. Nowak, N. J. et al. Genome-wide aberrations in pancreatic adenocarcinoma. Cancer Genet. Cytogenet. 161, 36-50 (2005). (Pubitemid 41096049)
106. Harada, T., Chelala, C., Crnogorac-Jurcevic, T. & Lemoine, N. R. Genome-wide analysis of pancreatic cancer using microarray-based techniques. Pancreatology 9, 13-24 (2009).
107. Calhoun, E. S. et al. Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. Cancer Res. 66, 7920-7928 (2006). (Pubitemid 44299154)
108. Harada, T. et al. Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene 27, 1951-1960 (2008). (Pubitemid 351430826)
109. Stoecklein, N. H. et al. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarincoma. J. Clin. Oncol. 22, 4737-4745 (2004).
110. Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer Nucleic Acids Res. 39, D945-D950 (2011).